Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Yemen Health Report.
Press releases published on September 11, 2025
A Landmark Pivotal Study Applying Precision Medicine to Psychiatry with Denovo’s DB104 (liafensine) for Treatment-Resistant Depression Published in JAMA Psychiatry
SAN DIEGO, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Denovo Biopharma LLC (Denovo), a pioneer in applying precision medicine to the development of innovative therapies, today announced that results from its pivotal ENLIGHTEN trial have been published as the …
First Patient Enrolled in DUBSTENT DIABETES Trial: Targeting Improved PCI Outcomes for Diabetic Patients
WAYNE, Pa., Sept. 11, 2025 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE:TFX), a leading global provider of medical technologies, today announced the enrollment of the first patient in the DUBSTENT DIABETES trial. The randomized, investigator-initiated …
RadioMedix and Vect-Horus Announce First Patient Dosed in Exploratory Clinical Study of 203Pb-RMX-VH-PIB for Glioblastoma Multiforme and Pancreatic Ductal Adenocarcinoma
HOUSTON and MARSEILLE, France, Sept. 11, 2025 (GLOBE NEWSWIRE) -- RadioMedix, Inc., a clinical-stage biotechnology company focused on innovative targeted radiopharmaceuticals for diagnosis, monitoring, and cancer therapy, and Vect-Horus, an expert in the …
GenVivo Strengthens Oncology Leadership with Appointment of Noriyuki Kasahara, M.D., Ph.D., as Chief Scientific Officer
Scientific Advisory Board member, Dr. Noriyuki Kasahara, appointed Chief Scientific Officer of GenVivo, to accelerate the achievement of major clinical milestones SAN MARINO, Calif., Sept. 11, 2025 (GLOBE NEWSWIRE) -- GenVivo, Inc., a clinical-stage …
Bioxodes positive Phase 2a stroke data show breakthrough potential of innovative therapeutic candidate BIOX-101
Safety endpoint met, with encouraging signs of efficacy in trial with 23 patients suffering from intracerebral hemorrhage (ICH) Findings suggest BIOX-101 reduced hematoma volume and slowed perihematomal edema growth Trend to functional recovery with BIOX- …
Les données positives de l’essai de phase 2a de Bioxodes montrent le fort potentiel de son candidat médicament innovant BIOX-101 dans l’AVC hémorragique
Le critère de sécurité a été atteint et des signes encourageants d’efficacité ont été observés lors de l’essai mené auprès de 23 patients touchés par un AVC hémorragique Les résultats suggèrent que BIOX-101 réduit le volume de l'hématome et ralenti la …
Scancell reports Business Update and Financial Results for the Year Ended 30 April 2025
NOTTINGHAM, United Kingdom, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Scancell Holdings plc (AIM: SCLP), the developer of ImmunoBody® and Moditope® active immunotherapies to treat cancer, today announces a business update and provides its final audited financial …
Press Release: Sanofi’s SAR402663 earns fast track designation in the US for neovascular age-related macular degeneration
Sanofi’s SAR402663 earns fast track designation in the US for neovascular age-related macular degeneration Designation earned for a one-time intravitreal gene therapy with the potential to eliminate treatment burden for people living with neovascular age- …
Communiqué de presse : Le SAR402663 de Sanofi a obtenu la désignation « fast track » aux États-Unis pour le traitement de la dégénérescence maculaire liée à l’âge néovasculaire
Le SAR402663 de Sanofi a obtenu la désignation « fast track » aux États-Unis pour le traitement de la dégénérescence maculaire liée à l’âge néovasculaire Désignation obtenue pour une thérapie génique intravitréenne unique avec le potentiel d’éliminer la …
Bioptimus Assembles Elite Scientific Advisory Board to Build Next-Gen AI Models for Biology
PARIS, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Bioptimus, the pioneering start-up building the world’s first universal foundation model for biology, today announced the formation of its Scientific Advisory Board (SAB), bringing together some of the most …
LB Pharmaceuticals Announces Pricing of its Upsized Initial Public Offering
NEW YORK, Sept. 10, 2025 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc (“LB Pharmaceuticals”) today announced the pricing of its upsized initial public offering of 19,000,000 shares of its common stock at a public offering price of $15.00 per share. The …